Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study describes teledermatology as a cost-effective and convenient alternative to in-person dermatology consultations during the COVID-19 pandemic, with diagnostic accuracy ranging from 54% to 88%.

This article discusses various limitations of direct-to-consumer teledermatology platforms, highlighting concerns regarding ethical issues, financial conflicts of interest, and challenges in providing comprehensive patient care compared to traditional in-person consultations.

This study found that ritlecitinib was well tolerated in children aged 6 to under 12 years with severe alopecia areata, with ongoing trials examining its efficacy and safety over a 24-week period and in long-term use up to 36 months.

Oral Vitamin D can improve hair density and reduce hair loss in Telogen Effluvium patients.

In this pilot study, both tofacitinib and methotrexate improved alopecia areata outcomes, but tofacitinib showed greater efficacy in achieving significant SALT score improvement after 6 months, although the difference was not statistically significant.

This review discusses the complex factors contributing to telogen effluvium, including stress and COVID-19, and highlights current understanding and future directions for treatment, but reports no new results.

In this randomized, placebo-controlled study, Titagen® was found to improve skin, hair, and nail health in adults consuming 5g daily, and reduce pain and improve quality of life for osteoarthritis patients taking 10g daily, without related adverse events.

This study found that prevelex coatings on microwell array devices enhanced the formation of uniform cell spheroids and enabled the development of hair follicles in tissue engineering applications.

In this six-year study of a Saudi cohort, oral tofacitinib showed favorable long-term effectiveness for patients with AA, with manageable adverse events requiring regular monitoring.

This study reports that a 21-year-old male with alopecia totalis responded positively to the JAK inhibitor tofacitinib, achieving complete hair regrowth after six months of treatment without significant side effects, though further research is needed to evaluate long-term efficacy.

This study found that tofacitinib and baricitinib, when administered with unorthodox weight-stratified dosing in pediatric patients with moderate-to-severe AA, showed comparable efficacy and tolerability, though baricitinib's efficacy decreased with non-standard dosing.

This case report details the successful use of oral tofacitinib for six months, which led to significant hair regrowth in an adult male Indian patient with extensive and refractory alopecia areata, highlighting tofacitinib's potential in managing resistant cases within this population.

This study evaluated a levan-based polysaccharide, POLEVAN®, in shampoo formulations and reported that it significantly increased hair glossiness by 24%, allowed a reduction of surfactant content by up to 50% without affecting foam, and maintained scalp moisturization similar to hyaluronic acid in a clinical setting.

This study suggests that observing the acute telogen effluvium triad—frontal fringe, temporal recess, and occipital fringe—can aid in diagnosing telogen effluvium during resolution phases, despite challenges like negative pull tests.

This study compared oral tofacitinib and methotrexate in treating moderate-to-severe alopecia areata, finding that tofacitinib was more effective at reducing SALT scores and improving scalp hair assessment PRO scores, though both treatments reduced psychological distress similarly without serious adverse effects.

This study found that engineered extracellular vesicles (293F-EGF-EV), enriched in EGF mRNA, significantly aided skin wound healing in vitro and in a rat model by promoting fibroblast activity and improving wound recovery through processes like angiogenesis and reduced scarring.

This study found that formulating raloxifene in nano-lipid carriers significantly enhanced its permeation and cytotoxicity against cancer cells compared to raw raloxifene.

This narrative review reported that direct-to-consumer teledermatology improves access to care, adherence, and patient satisfaction for treating male androgenetic alopecia, but may lead to higher drug costs.

In this study, tofacitinib treatment was associated with significant hair regrowth in two patients with alopecia universalis over eight months, with minimal adverse effects reported.

This review highlights that deucravacitinib, a selective TYK2 inhibitor, shows promise as an effective treatment for psoriasis and other inflammatory skin diseases, though real-world evidence beyond psoriasis is still emerging.

This study found that gene therapy using a mouse cytomegalovirus vector with telomerase reverse transcriptase or follistatin significantly extended lifespan and improved health markers in mice, without adverse effects.

This review discusses the use of tofacitinib as a treatment for plaque psoriasis, highlighting its efficacy and safety in clinical trials, but notes unresolved questions regarding long-term safety.

This study found that MOOEW Hair Tonic had a Return of Investment of over 100%, indicating significant potential for profitable and sustainable business opportunities.

In this study, inactivating the TAF4 subunit of transcription factor TFIID in mouse epidermis disrupted gene expression linked to skin and hair function, and increased tumor risk.

This study found that oral tofacitinib was effective and well tolerated for treating alopecia areata in most pediatric patients, with nearly 73% experiencing hair regrowth.

In this study, researchers analyzed 355 clinical trials from ClinicalTrials.gov, initiated by the end of 2025, to provide insights into the use of extracellular vesicles as circulating biomarkers or therapeutic interventions, highlighting current research priorities and future trends.

TEDAR is crucial for skin cell differentiation and barrier formation.

This study found that oral paclitaxel combined with encequidar improved tumor response rates compared to intravenous paclitaxel in women with metastatic breast cancer, while also reducing neuropathy but increasing certain gastrointestinal and neutropenic side effects.

This case series reported that telogen effluvium may reveal underlying traction alopecia, emphasizing the importance of recognizing this to ensure accurate diagnosis and treatment.

This review discusses the potential benefits and challenges of using extracellular vesicles in aesthetic medicine but reports no new clinical results, highlighting the need for rigorous validation and stronger regulatory oversight.